Literature DB >> 12130644

Peptides containing membrane-transiting motifs inhibit virus entry.

Hermann Bultmann1, Curtis R Brandt.   

Abstract

Several exceptional peptides have been identified that can cross plasma membranes and deliver various covalently linked moieties into cells. We report the surprising observation that each of four structurally distinct transiting peptides tested displayed antiviral activity and inhibited herpes simplex virus entry into cells. All four peptides inhibited infection at concentrations in the low micromolar range. Some of the peptides selectively and reversibly blocked entry without inactivating virions in a persistent manner. For other peptides, the effects on virus entry were not readily distinguishable from virus inactivation. High concentrations of nearly all peptides lead to irreversible inactivation of virions. By various criteria, the peptides differed in their ability to inactivate virions and in the temperature dependence of inactivation. Testing of peptides with modifications known to disrupt transport revealed that, in some instances, transport activity did not correlate with antiviral activity. These results identify inhibition of viral entry as another common property of membrane-transiting peptides in addition to their ability to cross membranes and transport materials into cells. These or related peptides may be useful as agents to prevent infection and to study the process of viral entry.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130644     DOI: 10.1074/jbc.M204849200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner.

Authors:  Hermann Bultmann; Gary Girdaukas; Glen S Kwon; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

2.  Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.

Authors:  Hermann Bultmann; Jeremy Teuton; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

3.  Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides.

Authors:  Radeekorn Akkarawongsa; Terra B Potocky; Emily P English; Samuel H Gellman; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

4.  A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.

Authors:  Inna V Larsen; Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2010-10-28       Impact factor: 2.671

Review 5.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

Review 6.  Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?

Authors:  Lena J Al-Dujaili; Patrick P Clerkin; Christian Clement; Harris E McFerrin; Partha S Bhattacharjee; Emily D Varnell; Herbert E Kaufman; James M Hill
Journal:  Future Microbiol       Date:  2011-08       Impact factor: 3.165

7.  A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro.

Authors:  Wei Hong; Yange Lang; Tian Li; Zhengyang Zeng; Yu Song; Yingliang Wu; Wenxin Li; Zhijian Cao
Journal:  J Biol Chem       Date:  2015-08-06       Impact factor: 5.157

8.  CAP37-derived antimicrobial peptides have in vitro antiviral activity against adenovirus and herpes simplex virus type 1.

Authors:  Y Jerold Gordon; Eric G Romanowski; Robert M Q Shanks; Kathleen A Yates; Heather Hinsley; H Anne Pereira
Journal:  Curr Eye Res       Date:  2009-03       Impact factor: 2.424

9.  Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells.

Authors:  Ling Yi; Zhengquan Li; Kehu Yuan; Xiuxia Qu; Jian Chen; Guangwen Wang; Hong Zhang; Hongpeng Luo; Lili Zhu; Pengfei Jiang; Lirong Chen; Yan Shen; Min Luo; Guoying Zuo; Jianhe Hu; Deliang Duan; Yuchun Nie; Xuanling Shi; Wei Wang; Yang Han; Taisheng Li; Yuqing Liu; Mingxiao Ding; Hongkui Deng; Xiaojie Xu
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.

Authors:  Gilbert G Jose; Inna V Larsen; Joshua Gauger; Erica Carballo; Rebecca Stern; Rachel Brummel; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-05       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.